The development of Ipamorelin arose from efforts to design a GHRP compound with a cleaner pharmacological profile than the earlier GHRPs
PubMed Sikiric, P., Seiwerth, S., Rucman, R., Turkovic, B., Rokotov, D.S., Brcic, L., Sever, M., Klicek, R., Radic, B., Drmic, D., Ilic, S., & Kolenc, D
Doege H, Grimm D, Falcon A, Tsang B, Storm TA, Xu H, Ortegon AM, Kazantzis M, Kay MA, Stahl A (2008) Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia
However, the primary pathway for glutahionylation and its reversal involves enzymes of the glutathione S-transferase family and glutaredoxin
Recommended dosage - 400mg three (3) times daily on an empty stomach to improve bioavailability
doi: 10.1038/s41598-019-40354-7 100 GotsmanIMuszkatM